Patient Experience Survey: Large B Cell Lymphoma with/without Lisocabtagene Maraleucel (Liso-cel; Breyanzi) CAR T-Cell Therapy |
Introduction
Thank you for your interest to take part in this online survey of patients & survivors. This survey will be used as part of Lymphoma Canada's submission to the Canadian Agency for Drugs and Technologies in Health (www.CADTH.ca), and the Quebec equivalent INESSS (Institut national d'excellence en santé et services sociaux). These agencies assess drugs for clinical and cost-effectiveness compared to other treatments that are currently available, and makes recommendations to provinces and territories to guide their drug funding decisions.
The purpose of this survey is to help develop a complete a thorough submission to help governments understand the value of new cancer drugs to patients. The drug that will soon be reviewed by CADTH/INESSS is for lisocabtagene maraleucel (also referred to as Liso-Cel or Breyanzi), and is a CAR T-Cell therapy. This treatment is being submitted for the treatment of adult patients with large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma (PMBCL), and DLBCL arising from follicular lymphoma, who are refractory or have relapsed within 12 months of first-line therapy and are candidates for autologous hematopoietic stem cell transplant (HSCT).
If you have Large B-Cell Lymphoma and have received treatment with Liso-cel or Breyanzi, your feedback is extremely important and may help improve access to this new drug for patients in Canada. The greater the response the better our data will be!
YOU DO NOT HAVE TO BE A CANADIAN RESIDENT TO RESPOND TO THIS SURVEY.
The purpose of this survey is to help develop a complete a thorough submission to help governments understand the value of new cancer drugs to patients. The drug that will soon be reviewed by CADTH/INESSS is for lisocabtagene maraleucel (also referred to as Liso-Cel or Breyanzi), and is a CAR T-Cell therapy. This treatment is being submitted for the treatment of adult patients with large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma (PMBCL), and DLBCL arising from follicular lymphoma, who are refractory or have relapsed within 12 months of first-line therapy and are candidates for autologous hematopoietic stem cell transplant (HSCT).
If you have Large B-Cell Lymphoma and have received treatment with Liso-cel or Breyanzi, your feedback is extremely important and may help improve access to this new drug for patients in Canada. The greater the response the better our data will be!
YOU DO NOT HAVE TO BE A CANADIAN RESIDENT TO RESPOND TO THIS SURVEY.
WE APPRECIATE INPUT FROM ALL LARGE B-CELL LYMPHOMA PATIENTS.
You can still participate if you have not been treated with lisocabtagene maraleucel (Liso-cel; Breyanzi).
If you have any questions, concerns, or technical difficulties while completing this survey please contact info@lymphoma.ca
Privacy Policy: To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used for the final submission to government agencies without reference to patient name or any other information that could lead to identifying the patient.
If you have any questions, concerns, or technical difficulties while completing this survey please contact info@lymphoma.ca
Privacy Policy: To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used for the final submission to government agencies without reference to patient name or any other information that could lead to identifying the patient.